RP2 Genetic Condition Registry
Part of Eyes & vision, Genetic & congenital clinical trials.
This registry study collects information from people who have a genetic change in the RP2 gene (a cause of inherited eye disease) and their families. It helps researchers learn more about the condition and how it affects daily life.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a genetic test result showing a change in the RP2 gene (either one copy or on the X chromosome).
- You (or your legal guardian) must be able to provide written permission (informed consent) to take part.
- You must be able to read and fill out forms in English or German.
- There is no age limit – patients of any age can join.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a gene therapy for people with a specific genetic form of retinitis pigmentosa (caused by changes in the RPGR gene). It aims to improve vision and slow disease progression.
This early study tests a gene therapy designed for people whose vision problems are caused by an RPGR genetic change. It may help slow or improve the eye disease by treating the underlying cause.
This study builds a registry and tracks the natural history of rare retinal dystrophies while also testing people for disease-causing gene variants. It may help researchers better understand what causes retinal degeneration and how it progresses.
This trial tests a new medicine, DSP-3077, given as a single injection into one eye to see if it is safe for people with retinitis pigmentosa. It is for adults with advanced vision loss who have no other major eye diseases.
This trial is a registry that collects health and genetic information from people with Rett syndrome. It may help researchers better understand how MECP2 loss-of-function changes lead to symptoms and how to support patients.
This trial is a registry that collects medical and genetic information from people with rhizomelic chondrodysplasia punctata (RCDP) or closely related conditions. It helps researchers better understand the condition and plan future studies that could lead to better care.
Hear when a new RP2-associated Retinitis Pigmentosa trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.